Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis
Thoracic Cancer · 2023-09 · 14 (25) · 2536-2547
DOI: 10.1111/1759-7714.15063 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Thoracic Cancer, online erschienen am 08.08.2023. Verfasst von Yu Feng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The aim of the study was to explore the efficacy and safety of immune checkpoint inhibitor (ICI) rechallenge in patients with non‐small cell lung cancer (NSCLC).
Methods
Studies that enrolled NSCLC patients treated with two lines of ICIs were included using four databases. The initial line (1L‐) and subsequent lines (2L‐) of ICIs were defined as 1L‐ICI and 2L‐ICI, respectively.
Results
A total of 17 studies involving 2100 patients were included. The pooled objective response rate (ORR), disease control rate (DCR), median progression‐free survival (mPFS), and median overall survival (mOS) for 2L‐ICIs were 10%, 50%, 3.0 months, and 13.1 months, respectively. The 2L‐ICI discontinuation rates caused by toxicities ranged from 0% to 23.5%. Original data were extracted from six studies, covering 89 patients. Patients in whom 1L‐ICIs were discontinued following clinical decision (the mPFS of 2L‐ICIs was not reach) achieved a more prolonged mPFS of 2L‐ICIs than those due to toxicity (5.2 months) and progressive disease (2.1 months) ( p < 0.0001). Patients' 1L‐PFS for more than 2‐years had preferable 2L‐ORR (35.0% vs. 9.8%, p = 0.03), 2L‐DCR (85.0% vs. 49.0%, p = 0.007), and 2L‐mPFS (12.4 vs. 3.0 months, p < 0.0001) than those less than 1‐year. Patients administered the same drugs achieved a significantly prolonged mPFS compared with the remaining patients (5.4 vs. 2.3 months, p = 0.0004), and those who did not accept antitumor treatments during the intervals of two lines of ICIs achieved a prolonged mPFS compared to those patients who did accept treatments (7.6 vs. 1.9 months, p < 0.0001).
Conclusions
ICI rechallenge is a useful therapeutic strategy for NSCLC patients, especially suitable for those who achieve long‐term tumor remission for more than 2‐years under 1L‐ICIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical…
- Department of Medical Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China.
- Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- Breast Tumor Center, Department of Medical Oncology, Phase I Clinical Trial Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regu…
- Thoracic Medicine Department II, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
- Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
ORCID-Profile: Yu Feng, Yunxia Tao, Xingsheng Hu, Yuankai Shi
Zitieren
APA
Feng, Y., Tao, Y., Chen, H., Zhou, Y., Tang, L., Liu, C., Hu, X., & Shi, Y. (2023). Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis. Thoracic Cancer, 14(25), 2536-2547. https://doi.org/10.1111/1759-7714.15063
Vancouver
Feng Y, Tao Y, Chen H, Zhou Y, Tang L, Liu C, et al. Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis. Thoracic Cancer. 2023;14(25):2536-2547. doi:10.1111/1759-7714.15063
BibTeX
@article{Feng2023,
author = {Feng, Yu and Tao, Yunxia and Chen, Haizhu and Zhou, Yu and Tang, Le and Liu, Chenwei and Hu, Xingsheng and Shi, Yuankai},
title = {Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis},
journal = {Thoracic Cancer},
year = {2023},
volume = {14},
number = {25},
pages = {2536--2547},
doi = {10.1111/1759-7714.15063}
}
EUVIMED